(Reuters) - European shares fell on Tuesday as Johnson & Johnson’s move to pause its COVID-19 clinical trials raised doubts about the timeline of a vaccine, while bank stocks tracked a slide in bond yields on bets of more stimulus by the European Central Bank.
A month after AstraZeneca AZN.L suspended late-stage trials of its vaccine candidate, Johnson & Johnson JNJ.N said it had temporarily halted trials due to an unexplained illness in a study participant.
“With numerous vaccines in the pipeline, this setback might not be viewed too negatively unless the unexplained illness becomes more expensive in other trials,” said Stephen Innes, a markets strategist at Axi.
Investors were also digesting mixed signals on more U.S. fiscal aid, with House Speaker Nancy Pelosi saying a recent offer from President Donald Trump fell far short of what the American people need, but added she still hoped a deal could be reached.
Hopes of more U.S. fiscal aid and signs of an economic rebound have powered European stock markets, helping the benchmark STOXX 600 on Monday to hit its highest close in nearly a month.
German investor sentiment fell more than expected in October on a triple whammy of coronavirus, Brexit and U.S. election angst, while in Britain, the unemployment rate rose in the three months to August to hit its highest in more than three years.
“UK unemployment is unfortunately set to rise further on the combined impact of fresh COVID-19 restrictions and the end of the original furlough scheme,” said ING economist James Smith.
In company news, Airbus SE AIR.PA fell 3.5% as JPMorgan cuts its rating on the planemaker's stock to "underweight" from "neutral".
British clothing retailer French Connection Group Plc FCCN.L slumped 19.6% in its worst session since March after posting a slump in first-half sales due to the health crisis.
Reporting by Sagarika Jaisinghani in Bengaluru; Editing by Arun Koyyur and Gareth Jones
Our Standards: The Thomson Reuters Trust Principles.